RecruitingPhase 2

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

Cedars-Sinai Department of Neurology

Los Angeles, California, United States

+19 additional locations

Contact

Clinical Trials at Denali Therapeutics

Save this trial

Cedars-Sinai Department of NeurologyLos Angeles, California, United States
University of California San FranciscoSan Francisco, California, United States
Parkinson's Disease and Movement Disorders CenterBoca Raton, Florida, United States
Beth Israel Deaconess Medical CenterBoston, Massachusetts, United States
Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder CenterNew York, New York, United States
Evergreen Health LaboratoryKirkland, Washington, United States
Inland Northwest ResearchSpokane, Washington, United States
Technische Universität DresdenDresden, Germany
University of LübeckLübeck, Germany
University Hospital TübingenTübingen, Germany
Rabin Medical CenterPetah Tikva, Israel
Movement Disorders Institute, Sheba Medical CenterRamat Gan, Israel
Tel Aviv Medical CenterTel Aviv, Israel
Hospital Clinic de BarcelonaBarcelona, Spain
Hospital Universitari General de CatalunyaBarcelona, Spain
Hospital Universitari Vall d'HebronBarcelona, Spain
Hospital Universitario DonostiaDonostia / San Sebastian, Spain
Universitary Hospital La PrincesaMadrid, Spain
IDIVAL/University Hospital Marques de ValdecillaSantander, Spain
Hospital Universitario Virgen del RocioSeville, Spain